Latest news about TruDiagnostic
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
TruDiagnostic has introduced Epigenetic Biomarker Proxies (EBPs), outperforming traditional lab results with 62% greater accuracy in disease prediction and 64% improved effectiveness in diagnosis. This involves non-invasive, cost-effective DNA methylation analysis from a single drop of blood, marking a significant advancement in precision medicine[2].
TruDiagnostic has launched the first-ever epigenetic aging analysis of individual organ systems, using validated and system-specific trained clocks developed by scientists at Yale University. This innovation allows for in-depth epigenetic results and multi-omic correlations to health, analyzing over 1,000,000 locations on one's DNA[4].
TruDiagnostic, in collaboration with Yale University, has conducted a landmark study analyzing the impact of 51 interventional trials on biological aging using DNAm biological aging clocks. This meta-analysis identified effective interventions to slow aging, providing concrete, data-driven insights into improving longevity through diet, exercise, pharmacological, and therapeutic modifications[5].
Open job positions at TruDiagnostic
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Bioinformatician
Molecular Lab Technician
Manager of Communications and Content

